Insulin infusion in acute illness
http://www.100md.com
《临床调查学报》
Division of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, and Kaleida Health, Buffalo, New York, New York, USA.
Abstract
The discovery of the antiinflammatory effect of insulin and the proinflammatory effect of glucose has not only provided novel insight into the mechanisms underlying several disease states but has also provided a rationale for the treatment of hyperglycemia in several acute clinical conditions. Van den Berghe et al. previously showed the benefits of intensive glycemic control with insulin in patients admitted to intensive care units. In this issue of the JCI, the same group of investigators now demonstrates that infusion of insulin to restore euglycemia in these patients results in a marked reduction in inflammatory indices such as adhesion molecules, hepatic iNOS, and plasma NO metabolites. The reduction in the mediators of inflammation may thus be responsible for the impressive improvement in clinical outcomes following insulin therapy, and the results suggest a new paradigm in which glucose and insulin are related not only through their metabolic actions but also through their opposite effects on inflammatory mechanisms.
See the related article beginning on page 2277
The importance of hyperglycemia in the pathogenesis and prognosis of acute illness and the benefit of controlling glucose with insulin in the critically ill hospitalized patient have emerged over the past 4 years. Three sets of data appeared almost simultaneously, which drew attention to this issue. First, glucose and lipid administration were shown to result in oxidative and inflammatory stress (1-3). Second, insulin, the hormone secreted in response to glucose and macronutrient intake, was found to suppress ROS generation and the activation of inflammatory mechanisms (4, 5). Thus, glucose was shown to be proinflammatory while insulin is antiinflammatory (Figure 1). Third, and almost simultaneously with the 2 previous studies, came the observation that the restoration of normoglycemia by insulin infusion in hyperglycemic patients in a surgical intensive care unit (ICU) resulted in a 50% reduction in mortality along with several other benefits, including a reduction in the incidence of renal failure (and thus the need for dialysis), septicemia, and ICU neuropathy (6). The need for blood transfusion and the duration of ventilation also fell significantly in these patients. These effects of insulin infusion in acutely ill patients were remarkable and totally unexpected. This large, landmark study provided clinical evidence that the proinflammatory effects of glucose and antiinflammatory effects of insulin probably play an important role in determining clinical outcome in acute illness. In this same study (6), the clinical benefits were associated with a fall in C-reactive protein level (7). A close relationship was found between the fall in blood glucose concentration and the improvement in clinical outcome.
Overall, the data emphasized that hyperglycemia is potentially toxic (6). This is consistent with a proinflammatory effect of glucose. In a subsequent publication, it was shown that there were marked mitochondrial abnormalities in the hepatocytes of the control group, which were prevented in the insulin infusion group with the restoration of normoglycemia (8). The mitochondrial abnormalities were characterized by marked swelling of the mitochondria, distortion of the cristae, and the separation of the inner mitochondrial membrane from the outer one. There was also an abnormality of the enzymes in the electron transport chain. The authors suggested that increased ROS generation and oxidative stress induced these abnormalities. This is consistent with the ROS-suppressive effect of insulin.
Mechanism of insulin action
Insulin suppresses 3 major proinflammatory transcription factors: NF-B, activator protein–1 (AP-1), and early growth response–1 (EGR-1) (4, 5). The genes regulated by these transcription factors encode monocyte chemoattractant protein 1, ICAM-1, MMP-2 and MMP-9, tissue factor (TF), and plasminogen activator inhibitor–1 (PAI-1) — are also suppressed by insulin (4, 5, 9) (Figure 1). Insulin infusion, in addition, suppresses pro–MMP-1 and PAI-1 in patients with acute myocardial infarction (9). MMP-1, a collagenase, lyses collagen in the shoulder regions of the atherosclerotic plaque, making it more vulnerable to rupture. Insulin may thus help stabilize the plaque. MMP-1 is known to activate protease-activated receptor–1, which mediates the action of thrombin and thus triggers prothrombotic and proconstrictor processes, which will also be potentially suppressed by insulin. In addition, insulin suppresses ROS generation and the expression of p47phox, a key component of NADPH oxidase, the enzyme that generates the superoxide radical, consistent with the potent antioxidant effect of insulin (4, 9). Two other important effects of insulin include vasodilatation and the inhibition of platelet aggregation (10-12). These effects are mediated by an increase in NO release and NO synthase activity in the endothelium and the platelet (13, 14). Platelet inhibition may also contribute to insulin’s antiinflammatory effect, since platelets are loaded with CD40 ligand, serotonin, and histamine.
Glucose: an inducer of oxidative stress and inflammation
Glucose, on the other hand, is proinflammatory, and even a 75-g glucose load given orally to normal subjects results in profound oxidative stress and inflammatory changes at the cellular and molecular level. This occurs even without an increase in plasma glucose concentrations into the pathological range and in spite of endogenous insulin secretion (1, 3). Therefore, if high plasma glucose concentrations are maintained, they can be expected to be profoundly proinflammatory. This is indeed the case, especially if endogenous insulin secretion is inhibited (15). Not only does glucose induce increased intranuclear NF-B binding, it induces increased AP-1 and EGR-1 binding. Thus, glucose activates all 3 key proinflammatory transcription factors suppressed by insulin (3, 16) (Figure 1). Generation of cytokines (e.g., TNF-) by mononuclear cells is stimulated in addition to an increase in MMP-2 and TF protein expression following the ingestion of glucose. In addition, plasma MMP-2, MMP-9, and TF concentrations increase (16). Glucose also induces an increase in ROS (including superoxide radical) generation and an increase in p47phox expression, which is consistent with an increase in NADPH oxidase (1). The bioavailability of NO is reduced due to the increase in the level of superoxide radical, which binds NO to form peroxynitrite. This exerts a proconstrictor, platelet proaggregatory, and prothrombotic effect. Through the induction of MMPs, glucose may promote plaque rupture and thus trigger thrombosis. Thus, hyperglycemia induces a milieu of oxidative stress, inflammation, vascular constriction, platelet hyperaggregability, and thrombosis. The proinflammatory and prothrombotic effects of glucose are profound.
The future of insulin infusions
Inflammation is a normal physiological defense mechanism. However, in severe inflammatory conditions, the excessive nature of this defense mechanism can contribute to tissue damage. Thus, its control could potentially improve clinical outcomes. Glucose is proinflammatory, and insulin is the ideal antiinflammatory measure, since it normalizes plasma glucose concentrations while exerting its antiinflammatory effect. In addition, insulin, as an anabolic hormone, could help control the catabolic state induced by severe inflammation. Thus, insulin infusion could potentially benefit conditions with severe systemic inflammation such as septicemia, meningitis, and pneumonias. The use of insulin infusions to maintain normoglycemia has already been shown to be of benefit during cardiac surgery (17), in patients with burns (18), and in those in medical ICUs (19). Furthermore, the antiinflammatory effect of insulin has been confirmed in rats injected with endotoxin (20) and in patients with severe forms of hyperglycemia including diabetic ketoacidosis (21). Similarly, insulin infusion has been shown to be antiinflammatory and cardioprotective in acute myocardial infarction (9).
A new study by Langouche, Van den Berghe et al., reported in this issue of the JCI (22), on ICU patients from the same cohort in which the authors previously established markedly improved survival (6), further emphasizes the role of insulin infusion in suppression of inflammation. Here they demonstrate, as might be expected, a suppression of several mediators of inflammation such as the adhesion molecules ICAM-1 and E-selectin (Figure 1). In addition, these patients had markedly elevated plasma NO (NO2 + NO3) concentrations as well as an increase in iNOS expression in the liver. Both plasma NO concentrations and iNOS expression were reduced by insulin, while eNOS expression was not altered. This very interesting observation implies that the source of the excessive NO is probably the iNOS expressed by macrophages in the liver (Kupffer cells). It is possible that the reticuloendothelial system elsewhere also contributes to this phenomenon. Insulin infusion likely suppresses iNOS expression not just in the liver but elsewhere. It is even more remarkable that the NO concentration predicted mortality: patients in the 2 highest quartiles of NO concentration had a risk ratio of 8.0 and 6.0, respectively, when compared with patients in the lowest quartile. This makes NO concentration the strongest risk factor for mortality in the ICU. Although the data on iNOS expression was obtained from the patients who died and therefore may not be precise, the marked suppression of iNOS, by 66%, following insulin infusion is consistent with a fall in NO. In contrast, eNOS levels did not change. This indicates that the contribution to the increase in NO concentration in these patients or the suppression of NO in those infused with insulin was not due to endothelial NO but due to iNOS from monocytes/macrophages or other cells in which iNOS has been induced as a result of inflammation (Figure 1). These data offer us the opportunity to use NO concentration as a prognostic marker and as an important mediator of the pathological process in ICU patients.
The data also demonstrate a small (15%) but significant reduction in ICAM-1, an adhesion molecule essential to the inflammatory response (22). The magnitude of this reduction is not likely to be responsible for the remarkable improvement in clinical outcomes, although it is consistent with an improvement in endothelial function.
More and more evidence of the antiinflammatory effect of insulin continues to emerge. The demonstration of its antiinflammatory action 80 years after its discovery as a metabolic hormone and more than 25 years after the discovery of the insulin receptor in the mononuclear cell (including the monocyte/macrophage), a key mediator of inflammation, is a major advance. Similarly, the emergence of glucose as an inducer of oxidative and inflammatory stress and a prognostic indicator of grave clinical outcomes offers important potential therapeutic opportunities. The outstanding studies discussed here represent significant advances in this rapidly developing field, and they support a new paradigm in which glucose and insulin are related not only through their metabolic action but also through inflammatory mechanisms.
Footnotes
Nonstandard abbreviations used: AP-1, activator protein–1; EGR-1, early growth response–1; ICU, intensive care unit; TF, tissue factor.
Conflict of interest: Paresh Dandona is a consultant and speaker for Sanofi-Aventis and Novo Nordisk.
References
Mohanty, P. et al. 2000. . Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J. Clin. Endocrinol. Metab. 85::2970-2973.
Tripathy, D. et al. 2003. . Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes. 52::2882-2887.
Dhindsa, S. et al. 2004. . Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear nuclear factor-kappaB in mononuclear cells. Metabolism. 53::330-334.
Dandona, P. et al. 2001. . Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect J. Clin. Endocrinol. Metab. 86::3257-3265.
Aljada, A., Ghanim, H., Mohanty, P., Kapur, N., and Dandona, P. 2002. . Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J. Clin. Endocrinol. Metab. 87::1419-1422.
Van den Berghe, G. et al. 2001. . Intensive insulin therapy in the critically ill patients. N. Engl. J. Med. 345::1359-1367.
Hansen, T.K., Thiel, S., Wouters, P.J., Christiansen, J.S., and Van den Berghe, G. 2003. . Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J. Clin. Endocrinol. Metab. 88::1082-1088.
Vanhorebeek, I. et al. 2005. . Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet. 365::53-59.
Chaudhuri, A. et al. 2004. . Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation. 109::849-854.
Grover, A. et al. 1995. . Insulin attenuates norepinephrine-induced venoconstriction. An ultrasonographic study. Hypertension. 25::779-784.
Steinberg, H.O., Brechtel, G., Johnson, A., Fineberg, N., and Baron, A.D. 1994. . Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J. Clin. Invest. 94::1172-1179.
Trovati, M. et al. 1994. . Insulin increases guanosine-3',5'-cyclic monophosphate in human platelets. A mechanism involved in the insulin anti-aggregating effect. Diabetes. 43::1015-1019.
Aljada, A., and Dandona, P. 2000. . Effect of insulin on human aortic endothelial nitric oxide synthase. Metabolism. 49::147-150.
Zeng, G., and Quon, M.J. 1996. . Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J. Clin. Invest. 98::894-898.
Esposito, K. et al. 2002. . Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 106::2067-2072.
Aljada, A. et al. 2004. . Glucose intake induces an increase in activator protein 1 and early growth response 1 binding activities, in the expression of tissue factor and matrix metalloproteinase in mononuclear cells, and in plasma tissue factor and matrix metalloproteinase concentrations. Am. J. Clin. Nutr. 80::51-57.
Furnary, A.P. et al. 2003. . Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. 125::1007-1021.
Jeschke, M.G., Klein, D., and Herndon, D.N. 2004. . Insulin treatment improves the systemic inflammatory reaction to severe trauma. Ann. Surg. 239::553-560.
Krinsley, J.S. 2004. . Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin. Proc. 79::992-1000.
Jeschke, M.G., Klein, D., Bolder, U., and Einspanier, R. 2004. . Insulin attenuates the systemic inflammatory response in endotoxemic rats. Endocrinology. 145::4084-4093.
Stentz, F.B., Umpierrez, G.E., Cuervo, R., and Kitabchi, A.E. 2004. . Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes. 53::2079-2086.
Langouche, L. et al. 2005. . Intensive insulin therapy protects the endothelium of critically ill patients. J. Clin. Invest. 115::2277-2286. doi:10.1172/JCI25385.(Paresh Dandona, Priya Moh)
Abstract
The discovery of the antiinflammatory effect of insulin and the proinflammatory effect of glucose has not only provided novel insight into the mechanisms underlying several disease states but has also provided a rationale for the treatment of hyperglycemia in several acute clinical conditions. Van den Berghe et al. previously showed the benefits of intensive glycemic control with insulin in patients admitted to intensive care units. In this issue of the JCI, the same group of investigators now demonstrates that infusion of insulin to restore euglycemia in these patients results in a marked reduction in inflammatory indices such as adhesion molecules, hepatic iNOS, and plasma NO metabolites. The reduction in the mediators of inflammation may thus be responsible for the impressive improvement in clinical outcomes following insulin therapy, and the results suggest a new paradigm in which glucose and insulin are related not only through their metabolic actions but also through their opposite effects on inflammatory mechanisms.
See the related article beginning on page 2277
The importance of hyperglycemia in the pathogenesis and prognosis of acute illness and the benefit of controlling glucose with insulin in the critically ill hospitalized patient have emerged over the past 4 years. Three sets of data appeared almost simultaneously, which drew attention to this issue. First, glucose and lipid administration were shown to result in oxidative and inflammatory stress (1-3). Second, insulin, the hormone secreted in response to glucose and macronutrient intake, was found to suppress ROS generation and the activation of inflammatory mechanisms (4, 5). Thus, glucose was shown to be proinflammatory while insulin is antiinflammatory (Figure 1). Third, and almost simultaneously with the 2 previous studies, came the observation that the restoration of normoglycemia by insulin infusion in hyperglycemic patients in a surgical intensive care unit (ICU) resulted in a 50% reduction in mortality along with several other benefits, including a reduction in the incidence of renal failure (and thus the need for dialysis), septicemia, and ICU neuropathy (6). The need for blood transfusion and the duration of ventilation also fell significantly in these patients. These effects of insulin infusion in acutely ill patients were remarkable and totally unexpected. This large, landmark study provided clinical evidence that the proinflammatory effects of glucose and antiinflammatory effects of insulin probably play an important role in determining clinical outcome in acute illness. In this same study (6), the clinical benefits were associated with a fall in C-reactive protein level (7). A close relationship was found between the fall in blood glucose concentration and the improvement in clinical outcome.
Overall, the data emphasized that hyperglycemia is potentially toxic (6). This is consistent with a proinflammatory effect of glucose. In a subsequent publication, it was shown that there were marked mitochondrial abnormalities in the hepatocytes of the control group, which were prevented in the insulin infusion group with the restoration of normoglycemia (8). The mitochondrial abnormalities were characterized by marked swelling of the mitochondria, distortion of the cristae, and the separation of the inner mitochondrial membrane from the outer one. There was also an abnormality of the enzymes in the electron transport chain. The authors suggested that increased ROS generation and oxidative stress induced these abnormalities. This is consistent with the ROS-suppressive effect of insulin.
Mechanism of insulin action
Insulin suppresses 3 major proinflammatory transcription factors: NF-B, activator protein–1 (AP-1), and early growth response–1 (EGR-1) (4, 5). The genes regulated by these transcription factors encode monocyte chemoattractant protein 1, ICAM-1, MMP-2 and MMP-9, tissue factor (TF), and plasminogen activator inhibitor–1 (PAI-1) — are also suppressed by insulin (4, 5, 9) (Figure 1). Insulin infusion, in addition, suppresses pro–MMP-1 and PAI-1 in patients with acute myocardial infarction (9). MMP-1, a collagenase, lyses collagen in the shoulder regions of the atherosclerotic plaque, making it more vulnerable to rupture. Insulin may thus help stabilize the plaque. MMP-1 is known to activate protease-activated receptor–1, which mediates the action of thrombin and thus triggers prothrombotic and proconstrictor processes, which will also be potentially suppressed by insulin. In addition, insulin suppresses ROS generation and the expression of p47phox, a key component of NADPH oxidase, the enzyme that generates the superoxide radical, consistent with the potent antioxidant effect of insulin (4, 9). Two other important effects of insulin include vasodilatation and the inhibition of platelet aggregation (10-12). These effects are mediated by an increase in NO release and NO synthase activity in the endothelium and the platelet (13, 14). Platelet inhibition may also contribute to insulin’s antiinflammatory effect, since platelets are loaded with CD40 ligand, serotonin, and histamine.
Glucose: an inducer of oxidative stress and inflammation
Glucose, on the other hand, is proinflammatory, and even a 75-g glucose load given orally to normal subjects results in profound oxidative stress and inflammatory changes at the cellular and molecular level. This occurs even without an increase in plasma glucose concentrations into the pathological range and in spite of endogenous insulin secretion (1, 3). Therefore, if high plasma glucose concentrations are maintained, they can be expected to be profoundly proinflammatory. This is indeed the case, especially if endogenous insulin secretion is inhibited (15). Not only does glucose induce increased intranuclear NF-B binding, it induces increased AP-1 and EGR-1 binding. Thus, glucose activates all 3 key proinflammatory transcription factors suppressed by insulin (3, 16) (Figure 1). Generation of cytokines (e.g., TNF-) by mononuclear cells is stimulated in addition to an increase in MMP-2 and TF protein expression following the ingestion of glucose. In addition, plasma MMP-2, MMP-9, and TF concentrations increase (16). Glucose also induces an increase in ROS (including superoxide radical) generation and an increase in p47phox expression, which is consistent with an increase in NADPH oxidase (1). The bioavailability of NO is reduced due to the increase in the level of superoxide radical, which binds NO to form peroxynitrite. This exerts a proconstrictor, platelet proaggregatory, and prothrombotic effect. Through the induction of MMPs, glucose may promote plaque rupture and thus trigger thrombosis. Thus, hyperglycemia induces a milieu of oxidative stress, inflammation, vascular constriction, platelet hyperaggregability, and thrombosis. The proinflammatory and prothrombotic effects of glucose are profound.
The future of insulin infusions
Inflammation is a normal physiological defense mechanism. However, in severe inflammatory conditions, the excessive nature of this defense mechanism can contribute to tissue damage. Thus, its control could potentially improve clinical outcomes. Glucose is proinflammatory, and insulin is the ideal antiinflammatory measure, since it normalizes plasma glucose concentrations while exerting its antiinflammatory effect. In addition, insulin, as an anabolic hormone, could help control the catabolic state induced by severe inflammation. Thus, insulin infusion could potentially benefit conditions with severe systemic inflammation such as septicemia, meningitis, and pneumonias. The use of insulin infusions to maintain normoglycemia has already been shown to be of benefit during cardiac surgery (17), in patients with burns (18), and in those in medical ICUs (19). Furthermore, the antiinflammatory effect of insulin has been confirmed in rats injected with endotoxin (20) and in patients with severe forms of hyperglycemia including diabetic ketoacidosis (21). Similarly, insulin infusion has been shown to be antiinflammatory and cardioprotective in acute myocardial infarction (9).
A new study by Langouche, Van den Berghe et al., reported in this issue of the JCI (22), on ICU patients from the same cohort in which the authors previously established markedly improved survival (6), further emphasizes the role of insulin infusion in suppression of inflammation. Here they demonstrate, as might be expected, a suppression of several mediators of inflammation such as the adhesion molecules ICAM-1 and E-selectin (Figure 1). In addition, these patients had markedly elevated plasma NO (NO2 + NO3) concentrations as well as an increase in iNOS expression in the liver. Both plasma NO concentrations and iNOS expression were reduced by insulin, while eNOS expression was not altered. This very interesting observation implies that the source of the excessive NO is probably the iNOS expressed by macrophages in the liver (Kupffer cells). It is possible that the reticuloendothelial system elsewhere also contributes to this phenomenon. Insulin infusion likely suppresses iNOS expression not just in the liver but elsewhere. It is even more remarkable that the NO concentration predicted mortality: patients in the 2 highest quartiles of NO concentration had a risk ratio of 8.0 and 6.0, respectively, when compared with patients in the lowest quartile. This makes NO concentration the strongest risk factor for mortality in the ICU. Although the data on iNOS expression was obtained from the patients who died and therefore may not be precise, the marked suppression of iNOS, by 66%, following insulin infusion is consistent with a fall in NO. In contrast, eNOS levels did not change. This indicates that the contribution to the increase in NO concentration in these patients or the suppression of NO in those infused with insulin was not due to endothelial NO but due to iNOS from monocytes/macrophages or other cells in which iNOS has been induced as a result of inflammation (Figure 1). These data offer us the opportunity to use NO concentration as a prognostic marker and as an important mediator of the pathological process in ICU patients.
The data also demonstrate a small (15%) but significant reduction in ICAM-1, an adhesion molecule essential to the inflammatory response (22). The magnitude of this reduction is not likely to be responsible for the remarkable improvement in clinical outcomes, although it is consistent with an improvement in endothelial function.
More and more evidence of the antiinflammatory effect of insulin continues to emerge. The demonstration of its antiinflammatory action 80 years after its discovery as a metabolic hormone and more than 25 years after the discovery of the insulin receptor in the mononuclear cell (including the monocyte/macrophage), a key mediator of inflammation, is a major advance. Similarly, the emergence of glucose as an inducer of oxidative and inflammatory stress and a prognostic indicator of grave clinical outcomes offers important potential therapeutic opportunities. The outstanding studies discussed here represent significant advances in this rapidly developing field, and they support a new paradigm in which glucose and insulin are related not only through their metabolic action but also through inflammatory mechanisms.
Footnotes
Nonstandard abbreviations used: AP-1, activator protein–1; EGR-1, early growth response–1; ICU, intensive care unit; TF, tissue factor.
Conflict of interest: Paresh Dandona is a consultant and speaker for Sanofi-Aventis and Novo Nordisk.
References
Mohanty, P. et al. 2000. . Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J. Clin. Endocrinol. Metab. 85::2970-2973.
Tripathy, D. et al. 2003. . Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes. 52::2882-2887.
Dhindsa, S. et al. 2004. . Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear nuclear factor-kappaB in mononuclear cells. Metabolism. 53::330-334.
Dandona, P. et al. 2001. . Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect J. Clin. Endocrinol. Metab. 86::3257-3265.
Aljada, A., Ghanim, H., Mohanty, P., Kapur, N., and Dandona, P. 2002. . Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J. Clin. Endocrinol. Metab. 87::1419-1422.
Van den Berghe, G. et al. 2001. . Intensive insulin therapy in the critically ill patients. N. Engl. J. Med. 345::1359-1367.
Hansen, T.K., Thiel, S., Wouters, P.J., Christiansen, J.S., and Van den Berghe, G. 2003. . Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J. Clin. Endocrinol. Metab. 88::1082-1088.
Vanhorebeek, I. et al. 2005. . Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet. 365::53-59.
Chaudhuri, A. et al. 2004. . Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation. 109::849-854.
Grover, A. et al. 1995. . Insulin attenuates norepinephrine-induced venoconstriction. An ultrasonographic study. Hypertension. 25::779-784.
Steinberg, H.O., Brechtel, G., Johnson, A., Fineberg, N., and Baron, A.D. 1994. . Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J. Clin. Invest. 94::1172-1179.
Trovati, M. et al. 1994. . Insulin increases guanosine-3',5'-cyclic monophosphate in human platelets. A mechanism involved in the insulin anti-aggregating effect. Diabetes. 43::1015-1019.
Aljada, A., and Dandona, P. 2000. . Effect of insulin on human aortic endothelial nitric oxide synthase. Metabolism. 49::147-150.
Zeng, G., and Quon, M.J. 1996. . Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J. Clin. Invest. 98::894-898.
Esposito, K. et al. 2002. . Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 106::2067-2072.
Aljada, A. et al. 2004. . Glucose intake induces an increase in activator protein 1 and early growth response 1 binding activities, in the expression of tissue factor and matrix metalloproteinase in mononuclear cells, and in plasma tissue factor and matrix metalloproteinase concentrations. Am. J. Clin. Nutr. 80::51-57.
Furnary, A.P. et al. 2003. . Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. 125::1007-1021.
Jeschke, M.G., Klein, D., and Herndon, D.N. 2004. . Insulin treatment improves the systemic inflammatory reaction to severe trauma. Ann. Surg. 239::553-560.
Krinsley, J.S. 2004. . Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin. Proc. 79::992-1000.
Jeschke, M.G., Klein, D., Bolder, U., and Einspanier, R. 2004. . Insulin attenuates the systemic inflammatory response in endotoxemic rats. Endocrinology. 145::4084-4093.
Stentz, F.B., Umpierrez, G.E., Cuervo, R., and Kitabchi, A.E. 2004. . Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes. 53::2079-2086.
Langouche, L. et al. 2005. . Intensive insulin therapy protects the endothelium of critically ill patients. J. Clin. Invest. 115::2277-2286. doi:10.1172/JCI25385.(Paresh Dandona, Priya Moh)